An investigational, non-hormonal peptide injection could offer women a way to treat ఎండోమెట్రియోసిస్ without shutting down their natural ovulation cycles, a potential turning point for the millions of Indian women who face a difficult trade-off between managing symptoms and trying to conceive. The therapy, called ENDO-205, is being developed by US-based biotech firm EndoCyclic Therapeutics and is currently in clinical development.
The latest endometriosis news from 2026 centres on ENDO-205, a first-in-class non-hormonal peptide therapy from EndoCyclic Therapeutics. Unlike standard endometriosis medications such as GnRH agonists and oral contraceptives, which work by suppressing estrogen and pausing ovulation, ENDO-205 is designed to target and clear diseased lesion tissue directly. This means women could potentially continue tracking their LH surges and trying to conceive during treatment. ENDO-205 remains investigational and is not yet commercially available in India or elsewhere (EndoCyclic Therapeutics, 2026; NIH SEED, 2024).
What Is the Latest Endometriosis News in 2026?
The most closely watched story in ఎండోమెట్రియోసిస్ research this year is the emergence of disease-modifying, non-hormonal therapies. ENDO-205, an investigational agent from EndoCyclic Therapeutics, has drawn attention because of how it approaches the condition.
Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, causing chronic pelvic pain, heavy periods, and, for many women, difficulty conceiving. According to the World Health Organization, endometriosis affects an estimated 10% of women of reproductive age globally, translating to a significant burden in India, where diagnostic delays average 7–10 years from the onset of symptoms.
Most endometriosis treatments available today rely on hormonal suppression. Medications like GnRH agonists and combined oral contraceptives control pain by lowering estrogen and pausing ovulation, essentially inducing a temporary medical menopause. For a woman trying to conceive, this creates a bind: treat the pain and pause fertility, or preserve fertility and live with the symptoms.
ENDO-205 is designed to change that equation. According to EndoCyclic Therapeutics’ pipeline disclosures, the therapy uses a proprietary peptide platform engineered to be selectively absorbed by diseased endometrial tissue outside the uterus. Once inside the lesions, it aims to activate the body’s natural clearance mechanisms, targeting the abnormal tissue directly rather than suppressing hormones throughout the body.
Why a Non-Hormonal Endometriosis Treatment Matters for Indian Women
For the Indian women who use fertility tracking tools, including the Premom app, to map their LH surges, basal body temperature (BBT), and cycle patterns, the significance of a non-hormonal therapy is substantial.
Standard endometriosis medication such as GnRH agonists flattens the natural hormonal peaks that make ovulation trackers, ovulation predictor kits (OPKs), and BBT charts meaningful. During treatment, LH surges do not occur, ovulation is halted, and active conception isn’t possible. Women are asked to pause their fertility journey, sometimes for months or years, to manage the condition.
ENDO-205 is designed to work without triggering this pause. Because it targets only the diseased tissue and doesn’t suppress estrogen or progesterone, the natural menstrual cycle is intended to continue during treatment. If clinical trials confirm this preservation of ovarian function, it would allow women to seek relief from endometriosis pain and lesion burden while simultaneously trying to conceive, a scenario current therapies cannot offer.
For Indian women dealing with the additional weight of long diagnostic delays and limited access to advanced fertility care outside metro cities, that dual capability could be meaningful.
ENDO-205 vs. Current Endometriosis Treatments
Source: EndoCyclic Therapeutics pipeline disclosures, 2026.
Beyond Endometriosis: Fibroids and Adenomyosis
The same peptide platform behind ENDO-205 is being explored for other conditions that affect fertility in Indian women, including uterine fibroids మరియు adenomyosis.
Uterine fibroids are non-cancerous muscular growths in the uterine wall that can distort the uterine cavity, cause heavy menstrual bleeding, contribute to implantation failure, and increase the risk of early miscarriage. Adenomyosis is a condition in which uterine lining tissue grows into the muscular wall of the uterus, causing severe cramping and fertility challenges. Both conditions are currently managed with limited options, often involving invasive surgery like myomectomy or hysterectomy in severe cases.
According to EndoCyclic Therapeutics, the tissue-targeting peptide platform is being adapted to identify and act on fibroid and adenomyosis tissue selectively. If successful, it could open a non-surgical pathway that preserves uterine health for future pregnancies.
FemLUNA: A Diagnostic Tool Also in Development
Alongside ENDO-205, EndoCyclic Therapeutics is developing an investigational imaging diagnostic called FemLUNA. Because a definitive endometriosis diagnosis often still requires laparoscopic surgery, the 7–10 year diagnostic delay remains one of the biggest problems facing women with the condition, particularly in India, where access to specialist care is uneven.
FemLUNA is being engineered to visualise endometriosis lesions, including superficial and sub-millimetre lesions that standard ultrasounds and MRIs typically miss, without radiation, heavy metals, or hormonal preparation. Paired with a targeted therapeutic like ENDO-205, the intention is to identify and treat the condition earlier, before it causes lasting damage to pelvic health or fertility.
What Should Women in India Do Right Now?
It is important to note that both ENDO-205 and FemLUNA are investigational agents. They must complete clinical trial phases and receive regulatory approval before becoming available. There is no current timeline for availability in India.
For Indian women managing endometriosis today:
- Consult a reproductive endocrinologist or gynaecologist for a full assessment. Current treatment options, including laparoscopic excision and medical therapy, remain the standard of care and can be effective when tailored to individual cases.
- If you’re trying to conceive, tracking ovulation with tools like the Premom app can help identify your fertile window. Many women with mild to moderate endometriosis conceive naturally with well-timed intercourse.
- Track your symptoms carefully. Detailed symptom logs help your doctor tailor treatment and can support faster diagnosis if endometriosis has not yet been confirmed.
Premom will continue to follow ENDO-205 and FemLUNA through their clinical development and will publish updates as they emerge.
ముఖ్యమైన అంశాలు
- ENDO-205 is an investigational non-hormonal peptide therapy for endometriosis, developed by EndoCyclic Therapeutics. It targets diseased tissue directly without suppressing ovulation.
- Current standard endometriosis treatments work through hormonal suppression, which pauses fertility during treatment.
- The same peptide platform is being adapted for uterine fibroids and adenomyosis, two other common conditions affecting Indian women’s reproductive health.
- FemLUNA, a companion non-invasive diagnostic tool, is also in development. It could help reduce India’s 7–10 year diagnostic delay.
- Both ENDO-205 and FemLUNA are investigational and not yet available to the public.
- Women in India managing endometriosis should continue working with their gynaecologist on current treatment options, and, if trying to conceive, track ovulation carefully to make the most of their fertile window.
Frequently asked questions about Endometriosis news
The most-discussed development is ENDO-205, an investigational non-hormonal peptide therapy from EndoCyclic Therapeutics designed to clear endometriosis lesions without suppressing ovulation. It is currently in clinical trials.
There is no cure for endometriosis at present. However, ENDO-205 represents a shift toward disease modification, aiming for durable lesion clearance rather than just symptom management. It has not yet completed clinical trials.
Yes. Many women with mild to moderate endometriosis conceive naturally. Fertility outcomes depend on the stage of the condition, ovarian reserve, and other factors. Tracking ovulation and timing intercourse during the fertile window remain the most actionable steps for women trying to conceive with endometriosis.
The gold standard for definitive diagnosis remains laparoscopic surgery, though imaging (transvaginal ultrasound, MRI) can identify some lesions. India’s average diagnostic delay from symptom onset is 7–10 years. Non-invasive diagnostics like FemLUNA are under development but not yet available.
There is no current timeline for availability. As an investigational drug, ENDO-205 must complete clinical trials and secure regulatory approval before being marketed anywhere. Premom will report updates as they become available.
Endometriosis can affect fertility, particularly in moderate to severe cases where adhesions or endometriomas are present. However, many women with endometriosis conceive naturally or with fertility support. A reproductive specialist can help assess individual fertility impact.
ప్రస్తావనలు
- Primary source (ENDO-205 pipeline): EndoCyclic Therapeutics. Our Pipeline: Targeted Peptides to Detect and Treat Disease at the Source. 2026. https://www.endocyclictherapeutics.com/pipeline
- Clinical funding & background: National Institutes of Health (NIH SEED). NIH Portfolio Company Showcase: EndoCyclic Therapeutics. U.S. Department of Health and Human Services; 2024. https://seed.nih.gov/portfolio/nih-portfolio-company-showcase/endocyclic-therapeutics
- General endometriosis context: ప్రపంచ ఆరోగ్య సంస్థ Endometriosis Fact Sheet. WHO; 2023. https://www.who.int/news-room/fact-sheets/detail/endometriosis
- Endometriosis in India: Federation of Obstetric and Gynaecological Societies of India (FOGSI). FOGSI-ICOG Endometriosis Guidelines. FOGSI; 2024.
నిరాకరణ: This news article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions about diagnosis or treatment.
